We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You must tell DVLA if you have muscular dystrophy - download the correct form to let them know.
UKHSA reminds eligible groups to come forward for mpox vaccination.
How to complete an air emissions risk assessment, including how to calculate the impact of your emissions and the standards you must meet.
This profile provides data on musculoskeletal conditions and services for local populations in England.
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
The BodyComm software currently uses Windows 10. Microsoft is transitioning to Windows 11 from 14 October 2025 which requires an updated cable to connect the pumps to the BodyComm software. These cables may not be available until after the Windows...
The first ever UK-US tech agreement will bring new healthcare breakthroughs, clean homegrown energy, and more investment into local communities and businesses in Britain and the United States.
Pioneering new cloud computer system will allow artificial intelligence (AI) tools to be tested on an unprecedented scale across the NHS to boost early diagnosis.
Skills England works with partners to create better skills for better jobs, enabling growth and opportunity. Skills England is an executive agency, sponsored by the Department for Education .
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (20 December 2024) granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne muscular dystrophy (DMD).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).